SI-2 has been verified to significantly inhibit breast cancer growth through a direct interaction with SRC-3, as well as to selectively reduce protein concentrations and transcriptional activities of SRC-3 without greatly affected cellular viability31. Here, NCOA3 is linked to breast carcinoma.